Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice

Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium.glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosano, Giuseppe, Quek, David, Martínez, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2020
Materias:
Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689869/
https://www.ncbi.nlm.nih.gov/pubmed/33294215
http://dx.doi.org/10.15420/cfr.2020.23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689869/
https://www.ncbi.nlm.nih.gov/pubmed/33294215
http://dx.doi.org/10.15420/cfr.2020.23

Ejemplares similares